1
|
Shan DD, Liu HM, Liu W, Huang WY, Lyu R, Deng SH, Yi SH, An G, Xu Y, Sui WW, Wang TY, Fu MW, Zhao YZ, Qiu LG, Zou DH. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:555-560. [PMID: 37749034 PMCID: PMC10509629 DOI: 10.3760/cma.j.issn.0253-2727.2023.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Indexed: 09/27/2023]
Abstract
Objective: This retrospective, single-center study aimed to evaluate the efficacy and safety of programmed death-1 (PD-1) inhibitors, either as monotherapy or in combination with chemotherapy, in the management of relapse/refractory classical Hodgkin's lymphoma (R/R cHL) . Methods: A total of 35 patients with R/R cHL who received treatment at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College from September 2016 to December 2020 were enrolled in this study. Among them, 17 patients received PD-1 inhibitor monotherapy (PD-1 inhibitor group), while 18 patients received a combination of PD-1 inhibitor and chemotherapy (PD-1 inhibitor + chemotherapy group). Clinical data and follow-up information were retrospectively analyzed, and survival analysis was conducted using the Kaplan-Meier method and Cox proportional hazards model. Results: The median age of the 35 patients with R/R cHL was 29 years (range: 11-61 years), with 54.3% being male. According to the Ann Arbor staging system, 62.9% of patients presented with advanced (stage Ⅲ/Ⅳ) disease, and 48.6% had extranodal involvement. Before PD-1 inhibitor therapy, the median number of prior lines of therapy was 2 (range: 1-3). Objective responses were observed in 28 patients, including 22 complete response (CR) cases, resulting in an overall response rate (ORR) of 80.0% and a CR rate of 62.9%. Specifically, the ORR and CR rates were 64.7% and 58.8%, respectively, in the PD-1 inhibitor group and 94.4% and 66.7%, respectively, in the PD-1 inhibitor + chemotherapy group. Among the 18 patients who underwent sequential autologous hematopoietic stem cell transplantation (auto-HSCT) [13 CR and five partial response (PR) cases], eight patients received PD-1 inhibitor therapy after auto-HSCT as consolidation therapy. All patients maintained a CR status after transplantation, and they exhibited significantly improved progression-free survival (PFS) rates compared with those who did not undergo sequential auto-HSCT (4-year PFS rates: 100% vs 53.5% ; P=0.041). The incidence of immune-related adverse events was 29%, with only one patient experiencing grade≥3 adverse reactions, which indicated a favorable safety profile for the treatment approach. Conclusions: PD-1 inhibitor monotherapy demonstrates notable efficacy and sustained response in patients with R/R cHL. PD-1 inhibitors combined with chemotherapy significantly improve response rates. Additionally, for salvage therapy-sensitive patients, consolidation treatment with PD-1 inhibitors after auto-HSCT exhibits the potential for prolonging PFS.
Collapse
Affiliation(s)
- D D Shan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - H M Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - W Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - W Y Huang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - R Lyu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - S H Deng
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - S H Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - G An
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - Y Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - W W Sui
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - T Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - M W Fu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - Y Z Zhao
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - D H Zou
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| |
Collapse
|
2
|
Xu JY, Yan WW, Fan HS, Liu JH, Du CX, Deng SH, Sui WW, Xu Y, Qiu LG, An G. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone]. Zhonghua Yi Xue Za Zhi 2022; 102:2338-2344. [PMID: 35970791 DOI: 10.3760/cma.j.cn112137-20211227-02906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the efficacy of VRD (bortezomib+lenalidomide+dexamethasone) in newly diagnosed multiple myeloma (NDMM) patients as well as the effect of the regimen on the long-term prognosis. Methods: The clinical characteristics, survival rates, response rates and minimal residual disease (MRD) of patients with NDMM at Institute of Hematology & Blood Diseases Hospital from January 1, 2013 to January 1, 2020 were retrospectively analyzed. Subgroup analysis was also performed among groups according to the cytogenetics and autologous stem cell transplantation (ASCT) of patients. Results: A total of 87 patients were retrospectively analyzed. The age[M(Q1,Q3)] of all patients was 56 (51, 61) years and males and females accounted for 58.6% (51/87) and 41.4% (36/87), respectively. The overall response rate (ORR) was 95.9% (71/74) after 2 courses of induction therapy, with 13.5% (10/74) achieving the deep response [complete response (CR) or better] and 51.3% (38/74) of patients achieving a very good partial response (VGPR) or better. After 4 courses of induction therapy, the ORR achieved 95.2% (60/63), and the proportions of the deep response and VGPR or better grew up to 46.0% (29/63) and 77.7% (49/63). According to the treatment, the patients (≤65 years old) were divided into transplantation group and non-transplantation group. After the induction therapy, 88.8% (32/36) of patients in the transplantation group achieved VGPR or better, and 55.5% (20/36) reached the deep response. After the transplantation, the proportion increased to 97.1% (34/35) and 77.2% (27/35), respectively(88.8% vs 97.1%,P=0.174;55.5% vs 77.2%,P=0.055), with the rate of undetectable MRD increasing from 44.4% (16/36) to 77.8% (28/36) (P=0.004). In the non-transplantation group, 74.2% (23/31) of patients achieved VGPR or better after 4 courses of induction therapy, 35.5% (11/31) of the patients achieved deep response and the rate of undetectable MRD was 37.0% (10/27). Compared with the non-transplantation group, transplantation was associated with a higher rate of complete response (89.5% vs 53.1%, P<0.001) and a lower rate of MRD detection(78.4% vs 55.2%, P=0.045). The median follow-up time of all patients was 26.3 months (20.8, 33.8). The median progression-free survival and overall survival were not reached. The three-year PFS and OS rates were 78.4% and 87.2%, respectively. None of the standard-risk group, the high-risk group, the transplantation group and non-transplantation group achieved the median PFS and OS. Conclusions: VRD regimen has a promising efficacy and results in a substantial survival benefit. ASCT after VRD induction therapy is associated with higher rate of deep response, higher rate of undetectable MRD and longer survival.
Collapse
Affiliation(s)
- J Y Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - W W Yan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - H S Fan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - J H Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - C X Du
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - S H Deng
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - W W Sui
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - Y Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| | - G An
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma and Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin 300020, China
| |
Collapse
|
3
|
Yan WW, Fan HS, Xu JY, Liu JH, Du CX, Deng SH, Sui WW, Xu Y, Qiu LG, An G. [Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma]. Zhonghua Nei Ke Za Zhi 2022; 61:801-805. [PMID: 35764565 DOI: 10.3760/cma.j.cn112138-20210908-00626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The clinical characteristics, laboratory results, response to treatment, and prognosis of 46 macrofocal multiple myeloma(MFMM) patients at our center from January 2013 to December 2019 were analyzed retrospectively. The other 92 patients were selected as matched-controls based on diagnostic period and treatment. Among the 1 137 MM patients, 46 patients met the definition criteria of MFMM (4.0%), with median age 56 years, which was not statistically different from whole MM population (P=0.066). According to the international staging system (ISS) and Revised ISS, the proportion of patients with advanced stage in MFMM group was less common than that of controls (P<0.05). More plasmacytomas in MFMM patients were presented (43.5% vs. 18.5%, P<0.05). Regarding cytogenetic abnormalities, there were minor patients manifesting high-risk features in MFMM group (15.8% vs. 32.2%, P=0.058). Translocation(11;14) could be detected in 32.4% MFMM patients and 9.4% typical myeloma patients (P<0.05). The treatment regimens were comparable. As to the best response of treatment, the complete response (CR) rate in MFMM group was significantly higher than that of controls (78.3% vs. 60.9%, P<0.05). The median follow-up time was 37.9 months. The median progression-free survival in MFMM and control groups were 77.5 vs. 39.8 months, respectively (P<0.05). The overall survival (OS) of MFMM patients was significantly longer (not reached vs. 68.2 months, P<0.05).
Collapse
Affiliation(s)
- W W Yan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H S Fan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J Y Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J H Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - C X Du
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Deng
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W W Sui
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - G An
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
4
|
Wang TY, Yi SH, Wang Y, Lyu R, Wang Q, Deng SH, Sui WW, Fu MW, Huang WY, Liu W, An G, Zhao YZ, Qiu LG. [Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:543-548. [PMID: 34455740 PMCID: PMC8408492 DOI: 10.3760/cma.j.issn.0253-2727.2021.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
目的 探讨FCR方案(氟达拉滨+环磷酰胺+利妥昔单抗)一线治疗慢性淋巴细胞白血病(CLL)的疗效。 方法 回顾性分析2004年5月至2017年12月一线应用FCR方案治疗的43例CLL患者的临床资料。 结果 ①43例CLL患者中,男31例,女12例,接受FCR方案治疗时中位年龄58(36~72)岁;8例患者伴B症状,外周血中位淋巴细胞计数26(3~550)×109/L,IGHV基因未突变62.1%(18/29),P53基因缺失14.0%(6/43),RB1基因缺失18.6%(8/43),12号染色体三体占25.6%(11/33),ATM基因缺失16.7%(7/42)。全部患者FCR方案中位疗程数为4(2~6)个。②全部43例患者的总体反应率(ORR)为88.4%(38/43),完全缓解(CR)20例(46.5%),部分缓解(PR)18例(41.9%),疾病稳定(SD)4例(9.3%),疾病进展(PD)1例(2.3%);7例(16.3%)患者获得微小残留病(MRD)阴性。③中位随访51(6~167)个月,中位无进展生存(PFS)时间为67(29~105)个月,中位总生存(OS)时间未达到,5年PFS率为(62.1±8.6)%,10年PFS率为(31.0±14.3)%,5年OS率为(70.5±8.3)%,10年OS率为(51.3±13.8)%。疗程数<4为影响OS的不良预后因素,P53基因缺失、疗程数<4为影响PFS的不良预后因素(P<0.001),且在多因素分析中仍具有预后意义[P53基因缺失:HR=7.65(95%CI 1.74~33.60),P=0.007;疗程数<4:HR=3.75(95%CI 1.19~11.80),P=0.025]。④18例(41.9%)患者于化疗后发生2~3级感染,19例(44.2%)发生3~4级血液学不良反应,1例(2.3%)患者发生肿瘤溶解综合征,所有不良反应经对症处理均恢复。 结论 FCR方案一线治疗CLL的治疗反应及远期生存较理想,不良反应可接受。
Collapse
Affiliation(s)
- T Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R Lyu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Q Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Deng
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W W Sui
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - M W Fu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W Y Huang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - G An
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Z Zhao
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
5
|
Liu JH, Fan HS, Deng SH, Sui WW, Fu MW, Yi SH, Huang WY, Li ZJ, Zhang CX, Zou DH, Zhao YZ, Qiu LG, An G. [Central nervous system toxicity caused by bortezomib: five case reports and a review of literature]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:63-69. [PMID: 33677871 PMCID: PMC7957256 DOI: 10.3760/cma.j.issn.0253-2727.2021.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
目的 探讨硼替佐米中枢神经系统(CNS)毒性的临床特点、诊断和治疗。 方法 报道5例由硼替佐米引起的CNS毒性患者并结合现有文献探讨其临床特点。 结果 5例患者中有4例在应用硼替佐米后出现了中枢性发热,主要表现为持续性高热、周身无汗、未能找到感染病灶、对退热药不敏感,停用硼替佐米后症状好转。4例患者中有3例伴随顽固性低钠血症,1例明确诊断为抗利尿不当综合征(SIAD),可能是硼替佐米同时影响了下丘脑体温调节中枢和抗利尿激素神经分泌细胞所致。1例患者诊断为可逆性后部脑病综合征(PRES),表现为应用硼替佐米后出现意识障碍,头CT示双侧半卵圆中心白质密度减低,停用硼替佐米后患者症状消失且未再复发。此外,我们还发现血小板计数可能与硼替佐米CNS毒性的严重程度相关。 结论 硼替佐米的CNS毒性非常罕见,表现为3种形式:SIAD、PRES和中枢性发热,及时识别和治疗对于预防不可逆的神经并发症非常重要。
Collapse
Affiliation(s)
- J H Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H S Fan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Deng
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W W Sui
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - M W Fu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W Y Huang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Z J Li
- Shandong Cancer Hospital, Jinan 250117, China
| | - C X Zhang
- Tangshan People's Hospital &Tangshan Cancer Hospital, Tangshan 063001, China
| | - D H Zou
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Z Zhao
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - G An
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
6
|
Lyu R, Yan YT, Yi SH, Wang TY, Deng SH, Liu W, Huang WY, An G, Sui WW, Zou DH, Qiu LG, Li ZJ. [The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:228-233. [PMID: 32311893 PMCID: PMC7357934 DOI: 10.3760/cma.j.issn.0253-2727.2020.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
目的 探讨24个月内疾病进展(POD24)对伴骨髓侵犯的脾边缘区淋巴瘤(SMZL)患者总生存的影响,比较POD24与非POD24患者的临床特征。 方法 回顾性分析2002年1月至2017年1月中国医学科学院血液病医院收治的有治疗指征且经过正规治疗的伴骨髓侵犯的SMZL患者,选取随访时间足以对POD24进行判断的患者(排除因非进展因素发生死亡的患者),进行预后评估及临床特征比较。 结果 共入组患者106例,中位年龄57(25~79)岁。①临床特征:全部患者均有骨髓侵犯和脾肿大,其中巨脾59.4%(63/106),肝大14.8%(15/101);复杂核型22.7%(18/79),13q缺失5.1%(4/78),11q缺失1.3%(1/72),17p缺失2.5%(2/80),12号染色体三体(CEP12)7.5%(4/53)。②生存分析:单因素分析提示POD24、HGB<100 g/L以及CEP12为与总生存相关的不良预后因素;多因素分析提示仅POD24有独立预后意义[HR=20.116(95%CI 2.226~181.820),P=0.008]。③亚组分析:POD24患者较非POD24患者起病时纵隔淋巴结肿大的发生率(63.6%对18.9%,P=0.005)及复杂核型发生率(50.0%对17.9%,P=0.024)明显增高;腹腔淋巴结肿大、贫血、血小板减少、白蛋白下降以及乳酸脱氢酶增高的发生率在POD24患者中更高,与非POD24患者相比差异无统计学意义(P>0.05)。 结论 POD24为影响伴骨髓侵犯的SMZL患者总生存的独立预后不良因素,起病时伴纵隔淋巴结肿大及复杂核型的患者发生POD24比例更高。
Collapse
Affiliation(s)
- R Lyu
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y T Yan
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - T Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S H Deng
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W Y Huang
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - G An
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - W W Sui
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D H Zou
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Z J Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
7
|
Qiu M, Zhang YW, Fei YY, Liu C, Deng SH, He W, Lu M, Lu J, Hou XF, Ma LL. [Retrospective study of diagnosis and treatment of renal oncocytoma]. Beijing Da Xue Xue Bao Yi Xue Ban 2019; 51:689-693. [PMID: 31420623 DOI: 10.19723/j.issn.1671-167x.2019.04.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To summarize the experience of diagnosis and surgical treatment of renal oncocytoma, and to evaluate the surgical results based on follow-up results, in order to find the best strategy. METHODS In the study, 21 cases with renal oncocytoma from December 2003 to April 2016 in Peking University Third Hospital were retrospectively analyzed, including 4 males, and 17 females, with 10 cases on the right side and 11 cases on the left side. Their age was between 15 to 80 years (average: 58 years). Ultrasound or CT examination after admission was conducted. Ultrasound examination showed solid nodules. CT manifestations were solid masses with enhancement, and the tumor size was between 1.5 cm to 6.5 cm (average: 3.3 cm). Of the 21 cases, 9 were located in the middle of kidney, 7 were located in the upper pole, and 5 were located in the lower pole. After preoperative examination, according to the size and location of the tumor, laparoscopic partial nephrectomy or laparoscopic nephrectomy was performed, respectively. RESULTS All the operations were successful, in which 17 cases underwent laparoscopic partial nephrectomy (including 3 cases which were converted to open surgery), and 4 cases underwent laparoscopic radical nephrectomy. The operation time ranged from 75 to 274 min (mean: 144 min), and the blood loss ranged from 10 to 1 000 mL (mean: 115 mL). The postoperative hospital stay time ranged from 6 to 13 d (average: 8.2 d). The pathological results were all renal oncocytoma. In the study, 17 cases were followed up while 4 cases were lost to follow-up. The follow-up time ranged from 12 to 175 months (mean: 44 months). One case died in 20 months after operation with unknown reason, and there were no recurrence or metastasis in the other 16 cases. CONCLUSION Renal oncocytoma is a benign tumor with good prognosis. Enhanced CT is an effective diagnostic method in assistant examination, but it is difficult to differentiate clear cell carcinoma only from the naked eye. It is worthwhile to measure CT value at different stages of the tumor by picture archiving and communication systems (PACS), and to compare with CT value of adjacent kidney tissue may improve the diagnostic efficiency of CT. Laparoscopic surgery is an effective treatment for renal oncocytoma. We recommend laparoscopic partial nephrectomy for the patients with renal oncocytoma as the best choice if conditions permit.
Collapse
Affiliation(s)
- M Qiu
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - Y W Zhang
- Department of Urology, Taiyuan People's Hospital, Taiyuan 030001, China
| | - Y Y Fei
- Department of Urology, Jixi Jikuang Hospital, Jixi 158100, Heilongjiang, China
| | - C Liu
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - S H Deng
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - W He
- Department of Radiology, Peking University Third Hospital, Beijing 100191, China
| | - M Lu
- Department of Pathology, Peking University Third Hospital, Beijing 100191, China
| | - J Lu
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - X F Hou
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L L Ma
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| |
Collapse
|
8
|
Wang TY, Li ZJ, Lin QS, Su D, Lyu R, Deng SH, Sui WW, Fu MW, Huang WY, Liu W, Liu H, Qiu LG. [Clinical and bacteriological analysis of lymphoid tissue neoplasms patients with bacteria bloodstream infections]. Zhonghua Xue Ye Xue Za Zhi 2019; 38:1043-1048. [PMID: 29365397 PMCID: PMC7342193 DOI: 10.3760/cma.j.issn.0253-2727.2017.12.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinical status of lymphoid tissue neoplasms patients with bacteria bloodstream infections, bacteriology and drug susceptibility results, and provide the basis for rational clinical anti-infection option. Methods: A retrospectively analysis of clinical data and bacterial susceptibility test results of patients with bacteria bloodstream infections from September 2010 to December 2014 was conducted. Results: A total of 134 cases including 107 patients with bloodstream infections were enrolled. 84 cases were male, 50 cases were female, the median age was 31 (12-71) years old. 112 cases were agranulocytosis, and 106 cases were severe agranulocytosis (ANC<0.1×10(9)/L) . 27 cases underwent hematopoietic stem cell transplantation, 100 cases received chemotherapy[33 cases with VD (I) CP±L (vincristine+daunorubicin/idarubicin + cyclophosphamide + prednison±asparaginasum) induction chemotherapy, 41 cases with intensive chemotherapy of Hyper-CVAD/MA or MA (mitoxantrone+cytarabine) , 26 cases with other chemotherapy regimens], and 7 cases were infected without chemotherapy. 10 patients discharged from hospital owing to treatment abandoning, 120 cases were cured through anti-infective therapy, 2 patients died of bacteria bloodstream infections, 1 patient died of sudden cardiac, and 1 patient died of GVHD after allogenic hematopoietic stem cell transplantation. A total of 144 strains were isolated, including 108 strains (75.0%) of Gram-negative bacteria and 36 strains (25.0%) of Gram-positive cocci. The susceptibility of Gram-negative bacteria to the carbapenems was 98.00%, and the adjustment treatment rate of carbapenems was 3.0%. The susceptibility of Gram-negative bacteria to the other antibiotics was 60.30%, and the adjustment treatment rate was 90.5%. The susceptibility of Grampositive cocci to the carbapenems was 49.3%, and to glycopeptides and linezolid was 100.0%. Comparing all patients'empirical use of antimicrobial agents with the drugs susceptibility results of blood cultures, 80.1% of the patients'initial drug selection was sensitive. Conclusion: The lymphoid neoplasms patients experienced bacteria bloodstream infections most often after receiving the chemotherapy regimens of treating acute lymphoblastic leukemia. The majority type of bacteria was Gram-negative bacteria. Drug susceptibility test showed that susceptibility of Gram-negative bacteria to the carbapenems was the highest, and the treatment adjustment rate was obviously lower. The susceptibility of Gram-positive cocci to glycopeptides and linezolid was high, and which could be applied to the patients with Gram-positive cocci sepsis on basis of susceptibility results in general.
Collapse
Affiliation(s)
- T Y Wang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zhu XQ, Guo CF, Wen YG, Shang DW, Hu JQ, Deng SH, Tan Y, Qiu C. Elevated PT, APPT and PT/INR possibly associated with doxycycline and cefoperazone co-administration: A case report. J Clin Pharm Ther 2017; 43:141-144. [PMID: 28850701 DOI: 10.1111/jcpt.12600] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Accepted: 06/26/2017] [Indexed: 01/04/2023]
Abstract
WHAT IS KNOWN AND OBJECTIVE Little is known regarding changes in blood coagulation parameters associated with tetracycline antibiotics. We report a possible case of elevated PT, APPT and PT/INR associated with doxycycline and cefoperazone co-administration. CASE SUMMARY An 83-year-old Chinese male inpatient with severe pneumonia, chronic renal insufficiency and malnutrition experienced elevated PT, APPT and PT/INR which occurred within a few days of doxycycline added to his cefoperazone treatment and returned to normal after removal of it. WHAT IS NEW AND CONCLUSION Very close monitoring of coagulation parameters might be advisable in those subjects when administering doxycycline and cefoperazone concomitantly.
Collapse
Affiliation(s)
- X Q Zhu
- Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - C F Guo
- Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - Y G Wen
- Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - D W Shang
- Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - J Q Hu
- Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - S H Deng
- Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - Y Tan
- Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - C Qiu
- Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| |
Collapse
|
10
|
Liu Z, Ma LL, Tian XJ, Wang GL, Hou XF, Zhang SD, Deng SH. [Radical nephrectomy and thrombectomy for Mayo clinic stage III tumor thrombus: a surgical technique and clinical experience]. Beijing Da Xue Xue Bao Yi Xue Ban 2017; 49:597-604. [PMID: 28816272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To evaluate the effectiveness and safety of radical nephrectomy and inferior vena cava thrombectomy in the treatment of patients with Mayo III tumor thrombus, and to introduce our experience and surgical technique. METHODS The clinical data of 8 patients with Mayo III tumor thrombus from October 2014 to September 2016 were analyzed retrospectively. Of the 8 patients, 3 were male and 5 were female. The average age was (50.8±18.7) years (18 to 77 years). The average body mass index (BMI) was (22.7±4.4) kg/m2 (15.2 to 30.8 kg/m2). Imaging suggested the right renal tumor in all the 8 cases. The average tumor size was (7.9±2.5) cm. Open radical nephrectomy and inferior vena cava thrombectomy was conducted in 5 cases and laparoscopic surgery in 3 cases, and 1 case was converted to open surgery. RESULTS All the 8 surgeries were completed successfully with no death case. The average surgery time was (370.3±101.6) min, ranging from 272-567 min. The average vena cava blocked time was (41.0±12.1) min, ranging from 17-55 min. The blood loss volume was (1 181.3±915.7) mL, ranging from 200-3 000 mL. During the operation, 5 cases were infused with suspended red blood cells, the amount of blood transfusion was 800-2 000 mL. 3 cases were infused of plasma with 400-1 000 mL. The average hospital stay was 9-23 d, with an average of (14.1±4.0) d. In the 8 patients, 4 cases underwent inferior vena cava wall resection because of invasion by tumor thrombus. Preoperative serum creatinine was 60-101 μmol/L, with an average of (76.4±15.3) μmol/L. Serum creatinine 1 week after the operation was 74-127 μmol/L, with an average of (100.8±21.1) μmol/L. Pathological diagnosis showed 6 cases of clear cell carcinoma, 1 case of papillary carcinoma type II, and 1 case of Ewing's sarcoma. Among the 8 patients, early postoperative complications occurred in 5 cases. Postoperative complications were graded as level II, according to the Clavien classifications. The 8 cases were followed up for 2 to 24 months with an average of 11.3 months. There was 1 patient who suffered from lung metastasis. CONCLUSION Our initial clinical results show that radical nephrectomy and inferior vena cava thrombectomy is safe and effective for patients with Mayo III tumor thrombus. The wide extension of grade III vein tumor thrombus leads to the difficulty of operation technique. Sufficient preoperative preparation, rich operative experience and skills can improve the safety of operation.
Collapse
Affiliation(s)
- Z Liu
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L L Ma
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - X J Tian
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - G L Wang
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - X F Hou
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - S D Zhang
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - S H Deng
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| |
Collapse
|
11
|
Liu W, Li J, Huang WY, Liu H, Li ZJ, Lv R, Deng SH, Fu MW, Sui WW, Wang TY, Qiu LG, Zou DH. [Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:548-551. [PMID: 28655103 PMCID: PMC7342966 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - D H Zou
- Department of Lymphoma and Myeloma, Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| |
Collapse
|
12
|
Sui WW, Zou DH, An G, Yi SH, Deng SH, Huang WY, Wang TY, Li J, Liu H, Fu MW, Lyu R, Liu W, Xu Y, Li ZJ, Zhao YZ, Qiu LG. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:499-504. [PMID: 28655093 PMCID: PMC7342971 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 评价诱导治疗联合自体周血造血干细胞移植(ASCT)治疗、移植后巩固维持治疗的整体方案治疗多发性骨髓瘤(MM)患者的有效性和长期随访结果。 方法 回顾性分析2005年1月1日至2016年2月1日接受整体方案治疗的144例MM患者资料,总结其长期随访结果,分析移植前疗效、移植后缓解深度,以及早期移植、晚期移植、不同预后分期系统等因素对患者生存的影响。 结果 144例患者中获得部分缓解(PR)以上治疗反应率为89.4%[完全缓解(CR)率64.1%]。中位随访47(6~121)个月,患者中位总体生存(OS)和无进展生存(PFS)时间分别为120.9和56.9个月;早期和晚期移植组患者的中位OS分别为120.9和50.1个月,中位PFS时间分别为60.2和16.7个月(P值均<0.001)。127例可进行修订的国际分期系统(R-ISS)分期患者中,Ⅰ期(43例)、Ⅱ期(64例)、Ⅲ期(20例)患者的中位OS时间分别为120.9、88.4、35.6个月,组间差异有统计学意义(P=0.000)。对早期和晚期移植组患者进行亚组生存分析,R-ISS Ⅲ期患者中位OS时间差异有统计学意义(35.6个月对15.8个月,P=0.031);两组患者各期中位PFS时间差异均有统计学意义(Ⅰ期:72.1个月对18.9个月;Ⅱ期:53.4个月对16.7个月;Ⅲ期:28.5对5.9个月,P值分别为0.000、0.012、0.001)。多因素分析结果显示R-ISS Ⅲ期是影响患者OS的危险因素(HR=8.486,95%CI 2.549~28.255,P=0.003),移植后未获得CR是影响患者PFS的危险因素(HR=2.412,95%CI 1.364~4.266,P=0.002)。 结论 以新药为基础的化疗联合ASCT的整体治疗方案对适合移植的MM患者是有效的,可进一步提高缓解率和缓解深度,延长患者的PFS和OS时间。早期较晚期移植可明显延长患者的OS和PFS时间。R-ISS分期和移植前疗效是影响患者生存的预后因素。
Collapse
Affiliation(s)
- W W Sui
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Deng SH, Xu Y, Sui WW, An G, Mao XH, Li ZJ, Zou DH, Qiu LG. [Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:487-493. [PMID: 28655091 PMCID: PMC7342977 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
目的 探讨来那度胺(商品名瑞复美)为基础的化疗方案在复发或难治性多发性骨髓瘤(MM)患者中的疗效及安全性。 方法 回顾性分析2013年6月至2016年2月收治的57例应用来那度胺为基础的方案治疗的复发或难治性MM患者资料。 结果 ①国际分期系统(ISS)Ⅲ期患者比例为60.4%,修改的国际分期系统(R-ISS)Ⅲ期患者比例为37.9%,53.3%的患者存在高危遗传学异常。②患者应用来那度胺中位疗程为6(1~32)个。治疗的总体缓解率(ORR)为58.9%(33/56),其中完全缓解率为8.9%,非常好的部分缓解率为19.8%,部分缓解(PR)率为30.4%。此外有10.7%(6/56)的患者达到微小缓解,临床获益率69.6%。前期接受一线以上治疗、既往沙利度胺耐药及R-ISS Ⅲ期患者ORR较低。③中位随访27个月,患者中位无进展生存(PFS)时间8个月,中位达PR时间2个月,中位缓解持续时间(DOR)8个月,中位总体生存(OS)时间19个月。单因素分析中,染色体核型异常、R-ISS分期Ⅲ期、疗效未达PR及以上是影响患者PFS和OS的不良因素。多因素分析显示,染色体核型异常、R-ISS分期Ⅲ期具有独立预后意义。④安全性分析显示,最常见的3/4级非血液学不良反应为感染(17.5%)、皮疹(1.8%)、血栓(1.8%)。最常见的3/4级血液学不良反应为中性粒细胞减少(7.0%)和血小板减少(3.5%)。共有3例(5.3%)患者因不良反应停药。共观察到第二肿瘤2例(3.5%)。 结论 来那度胺为基础的化疗方案在复发或难治性MM患者中有效率高、耐受性良好。预后因素分析显示,在这一患者群体中染色体核型异常、R-ISS分期Ⅲ期是独立预后不良因素。
Collapse
Affiliation(s)
- S H Deng
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Zhong ZL, Yang QM, Deng SH, Zhong C, Huang RC. [The clinical efficacy analysis of the surgery of the posterior approach parotid gland region resection preserving retinal ganglion and parotid fascia]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017; 31:616-618. [PMID: 29871327 DOI: 10.13201/j.issn.1001-1781.2017.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 11/06/2016] [Indexed: 11/12/2022]
Abstract
Objective:To explore the clinical efficacy analysis the surgery of the posterior approach parotid gland resection preserving retinal ganglion and parotid fascia for the treatment of benign parotid tumour.Method:One hundred and twelve cases were randomly divided into control group and treatment group. The control group was treated by anterior approach parotid gland region resection preserving retinal ganglion and parotid fascia. The treatment group was treated by posterior approach parotid gland region resection preserving retinal ganglion and parotid fascia. The data of operation time, postoperative local numbness, Frey syndrome, facial paralysis and postoperative recurrence case were analyzed. Result:There was no postoperative recurrence case in both two groups, and there was no significant difference between two the groups in operation time and the percent of facial paralysis(all P>0.05).However, the percent of postoperative local numbness and Frey syndrome in control group were significantly higher than those in treatment group(all P<0.05). Conclusion:The treatment group had similar clinical efficacy with the traditional surgical operation. In addition, the operation of treatment group contributed to decreased postoperative complications.
Collapse
Affiliation(s)
- Z L Zhong
- Department of Otorhinolaryngology Head and Neck Surgery,the Pingxiang People's Hospital, Pingxiang, Jiangxi Province,337000,China
| | - Q M Yang
- Department of Otorhinolaryngology Head and Neck Surgery,the Pingxiang People's Hospital, Pingxiang, Jiangxi Province,337000,China
| | - S H Deng
- Department of Oral and Maxillofacial Surgery,the Pingxiang People's Hospital
| | - C Zhong
- Department of Otorhinolaryngology Head and Neck Surgery,the Pingxiang People's Hospital, Pingxiang, Jiangxi Province,337000,China
| | - R C Huang
- Department of Oral and Maxillofacial Surgery,the Pingxiang People's Hospital
| |
Collapse
|
15
|
Zhang HX, Zhao L, Ma LL, Hou XF, Liu L, Deng SH. [Retroperitoneal laparoscopic nephrectomy with autotransplantation for severe iatrogenic ureteral injury]. Beijing Da Xue Xue Bao Yi Xue Ban 2016; 48:622-626. [PMID: 29263501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To evaluate the safety and efficacy of retroperitoneal laparoscopic nephrectomy with autotransplantation in cases of severe iatrogenic proximal ureteral damage. METHODS From July 2011 to March 2015, two patients, aged 44 (female) and 54 years (male), underwent retroperitoneal laparoscopic nephrectomy and autotransplantation for treatment of severe iatrogenic proximal ureteral injuries. Both injuries were proximal ureteral avulsion during ureterolithotomy with the holmium laser for ureteral calculi. computed tomography angiography (CTA) and computed tomography urography (CTU) was performed in both patients before operation. A 3-port retroperitoneal technique was used for the patients placed in a lateral decubitus position. A retroperitoneal laparoscopic nephrectomy with autotransplantation approach was used in both the patients, and the kidneys were removed to the right iliac fossa. Case 1's kidney was removed through the right Gibson incision, while Case 2's kidney was removed through the left lumbar incision. The renal artery and renal vein were ligated using the Hem-o-lok. The kidneys were taken out quickly from the patients and infused with 4 °C kidney preserving fluid immediately. RESULTS The retroperitoneal laparoscopic nephrectomy with autotransplantations was performed 4 hours in Case 1 and 2 years in Case 2 after atrogenic proximal ureteral injuries. Case 2 was associated with dense perinephric and perihilar fibrosis. The procedures were successful, with immediate return of renal function in both the patients. After ex vivo graft preparation, ureteral and vessel length and quality were adequate for transplantation in both the cases. A direct ureterovesical anastomosis was performed in both patients. In the 2 patients, the warm ischemia time was 3 and 5 minutes, the total operation time 185 and 246 minutes, and the estimated blood loss 70 and 200 mL, respectively. No perioperative complications occurred. At the end of the follow-up, the transplanted kidneys were functional, and the patients had returned to their normal activity. CONCLUSION Retroperitoneal laparoscopic nephrectomy with autotransplantation is an excellent alternative to nephrectomyor bowel interposition in patients with proximal ureteral loss. This procedure is associated with acceptable morbidity and preserves the renal function. This report supports the safety and efficacy of retroperotoneal laparoscopic nephrectomy with autotransplantation in experienced hands.
Collapse
Affiliation(s)
- H X Zhang
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L Zhao
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L L Ma
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - X F Hou
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L Liu
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - S H Deng
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| |
Collapse
|
16
|
Zhang HX, Zhao L, Ma LL, Hou XF, Liu L, Deng SH. [Retroperitoneal laparoscopic nephrectomy with autotransplantation for severe iatrogenic ureteral injury]. Beijing Da Xue Xue Bao Yi Xue Ban 2016; 48:622-626. [PMID: 27538140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVE To evaluate the safety and efficacy of retroperitoneal laparoscopic nephrectomy with autotransplantation in cases of severe iatrogenic proximal ureteral damage. METHODS From July 2011 to March 2015, two patients, aged 44 (female) and 54 years (male), underwent retroperitoneal laparoscopic nephrectomy and autotransplantation for treatment of severe iatrogenic proximal ureteral injuries. Both injuries were proximal ureteral avulsion during ureterolithotomy with the holmium laser for ureteral calculi. computed tomography angiography (CTA) and computed tomography urography (CTU) was performed in both patients before operation. A 3-port retroperitoneal technique was used for the patients placed in a lateral decubitus position. A retroperitoneal laparoscopic nephrectomy with autotransplantation approach was used in both the patients, and the kidneys were removed to the right iliac fossa. Case 1's kidney was removed through the right Gibson incision, while Case 2's kidney was removed through the left lumbar incision. The renal artery and renal vein were ligated using the Hem-o-lok. The kidneys were taken out quickly from the patients and infused with 4 °C kidney preserving fluid immediately. RESULTS The retroperitoneal laparoscopic nephrectomy with autotransplantations was performed 4 hours in Case 1 and 2 years in Case 2 after atrogenic proximal ureteral injuries. Case 2 was associated with dense perinephric and perihilar fibrosis. The procedures were successful, with immediate return of renal function in both the patients. After ex vivo graft preparation, ureteral and vessel length and quality were adequate for transplantation in both the cases. A direct ureterovesical anastomosis was performed in both patients. In the 2 patients, the warm ischemia time was 3 and 5 minutes, the total operation time 185 and 246 minutes, and the estimated blood loss 70 and 200 mL, respectively. No perioperative complications occurred. At the end of the follow-up, the transplanted kidneys were functional, and the patients had returned to their normal activity. CONCLUSION Retroperitoneal laparoscopic nephrectomy with autotransplantation is an excellent alternative to nephrectomyor bowel interposition in patients with proximal ureteral loss. This procedure is associated with acceptable morbidity and preserves the renal function. This report supports the safety and efficacy of retroperotoneal laparoscopic nephrectomy with autotransplantation in experienced hands.
Collapse
Affiliation(s)
- H X Zhang
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L Zhao
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L L Ma
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - X F Hou
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - L Liu
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| | - S H Deng
- Department of Urology, Peking University Third Hospital, Beijing 100191, China
| |
Collapse
|
17
|
Deng SH, Zhao JJ, Lin QF, Fan CJ, Zhou XD. Formation of interfacial network structure via photo-crosslinking in carbon fiber/epoxy composites. EXPRESS POLYM LETT 2014. [DOI: 10.3144/expresspolymlett.2014.54] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
Deng SH, Zhou XD, Zhu MQ, Fan CJ, Lin QF. Interfacial toughening and consequent improvement in fracture toughness of carbon fiber reinforced epoxy resin composites: induced by diblock copolymers. EXPRESS POLYM LETT 2013. [DOI: 10.3144/expresspolymlett.2013.90] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
19
|
Yuan FS, Guo SL, Qiu ZX, Deng SH, Huang GH. [Effect of dibutyl phthalate on demodicidosis]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003; 19:160-2. [PMID: 12571942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
OBJECTIVE To evaluate the curative effect and safety of dibutyl phthalate on demodicidosis. METHODS A single blinded and controlled study of human demodicidosis treated with dibutyl phthalate was conducted. One hundred and forty three patients with demodicidosis, including 81 acne and 62 rosacea, randomly divided into trial and control groups. The trial group was treated with dibutyl phthalate and control group with "new fumanling" cream twice a day in the early morning and evening respectively for six weeks consecutively. RESULTS The rates of excellent, good, and fair efficacy and total effective rate in the trial group with acne were 53.7%, 41.5%, 4.9% and 100% respectively, with a significant difference to the control group (P < 0.05). The rates in the trial group with rosacea were 40.6%, 40.6%, 18.8% and 100% respectively, with no statistical difference to the control group (P > 0.05). No complaint of side effects in the trial group was recorded. CONCLUSION Dibutyl phthalate is highly effective to demodicidosis without prominent adverse reactions.
Collapse
Affiliation(s)
- F S Yuan
- Department of Parasitology, Medical Collage of Shandong University, Jinan 250012
| | | | | | | | | |
Collapse
|
20
|
Song WD, Zhang AC, Pang YY, Liu LH, Zhao JY, Deng SH, Zhang SY. Fibronectin and hyaluronan in bronchoalveolar lavage fluid from young patients with chronic obstructive pulmonary diseases. Respiration 1995; 62:125-9. [PMID: 7569331 DOI: 10.1159/000196406] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Fibronectin (FN) and hyaluronan (HA) in bronchoalveolar lavage fluid (BALF) and FN released by alveolar macrophages (AM) were examined in 7 nonsmoking healthy control subjects, and 20 smoking patients with chronic obstructive pulmonary diseases (COPD). All patients and subjects were no more than 40 years old. According to the 95% confidence limits of HA and FN in BALF from nonsmoking healthy control subjects, the smoking patients were divided into two groups, those who had HA and FN levels within the limits for nonsmoking controls were classified as the first group (group 1) and those with levels above the control limits were classified as the second group (group 2). Our data showed that the concentrations of HA and FN in BALF and FN released by AM were significantly higher in group 2 than in group 1 patients. There were also significant differences between the two groups in pulmonary function measurements (DLco, FEV1, and FEV1/FVC) which were lower in group 2. HA levels in group 2 patients correlated directly with counts of inflammatory cells in BALF (BALF cells/ml, and numbers/ml of total cells, macrophages, neutrophils and lymphocytes), and the concentration of FN released by AM, and showed an inverse correlation with pulmonary function (DLco and FEV1/FVC). Our results suggest that the inflammatory repair response and fibrosis may play a role in the development of emphysema in young patients with COPD.
Collapse
Affiliation(s)
- W D Song
- Department of Pulmonary Medicine, First Affiliated Hospital, Anhui Medical University, PR China
| | | | | | | | | | | | | |
Collapse
|
21
|
Deng SH, Chen JS. Clinical application of the determination of serum guanase activity. Taiwan Yi Xue Hui Za Zhi 1969; 68:367-71. [PMID: 5259195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
22
|
Deng SH, Chang TC, Li CT, Ho GB, Wang MT. [Cardiotonic action of Tupistra aurantiaca wall]. Yao Xue Xue Bao 1965; 12:788-92. [PMID: 5899055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|